• Founded in 1967, GC Pharma is a leading biomedical engineering company that has developed pharmaceuticals that are difficult to build, but are indispensable.
• With a product portfolio that runs the gamut of specialty and commodity medicinal products, including blood products, vaccines, and a popular cataplasm name Zenol, GC Pharma has sustained its reputation as an R&D-driven pharmaceutical company as it has successfully developed innovative products, including GreenGene F, the world’s fourth drug designed to treat genetic recombination hemophilia A, and Hunterase, the world’s second drug to treat Hunter syndrome.
• GC Pharma whose exports hit the $100 million mark in 2013 with completion of a blood product production plant in Thailand continues to expand its international presence and to grow as one of the major global players in the healthcare industry as it recently signed an agreement to build another blood product production plant in North America.

• GC Wellbeing is a newly established company through Green Cross JBP acquiring Green Cross HS and GC Wellbeing operation division.
• In order to become a leader of Healthcare Solution in an era of longevity, we not only offer personalized Healthcare Solution such as individual customized nutrient medication and health supplement food, but also research and develop natural medical supplies and health functional food.

• GC MEDIS corp. was established in 2005 as a specialized POCT (point-of-care test) company based on IT and Bio convergence technology in the mobile health care and in vitro diagnostic business under the motto of "Bio -IT technology for human, We find the answers from a drop of blood.".
• We are developing a multi-measurement system for point-of-care diagnosis that combines glycated hemoglobin(HbA1c), inflammatory markers(CRP), kidney disease(U-albumin), and blood coagulation (D-Dimer) markers for point-of-care diagnosis along with accurate and high-quality blood glucose measurement system products.

• GC Lab Cell was formed from the merger of GC cell therapy and cord blood storage divisions.
• GC Lab Cell has the goal of developing cell immunotherapies based on NK cells and treatments for intractable diseases using stem cells. The company plans to expand its business portfolio into other stem cell therapies and distribute its technologies and products worldwide.

• A subsidiary of the GC Group specializing in genetic analysis, GC Genome provides a broad spectrum of diagnostic services, including pre-implantation genetic tests (PGTs), analysis of cancer genes, and predicting individual reactions to drugs.
• The company plans to acquire a next-generation genetic sequencing analyzer and other large capacity genetic testing equipment in order to develop more innovative diagnostic techniques and personalized medicines.

• GC care is involved in IT platform business, specialized in digital healthcare services focused on data and mobile experience.
• Our goal is to help everyone live healthy by medical checkup, self-diagnosis, managing daily health record through healthcare portal everywhere.
• We are contributing to provide comprehensive care service such as ‘Employee Wellness program’ to more company, also we are expanding our role as a ‘smart care coordinator’ for management of patients with chronic illnesses.

Established in Hong Kong to facilitate an IPO in China, GCHK is the parent company of GC China and plays a pivotal role in financing its subsidiary.

GC China, established as part of GC Pharma’ global expansion strategy, produces plasma-derived products. Since passing the Chinese National Health and Family Planning Commission of the People’s Republic of China’s on-site inspection and obtaining a safety certificate in 1998, the company has gone on to become the first in Anhui Province to satisfy the Chinese government’s Good Manufacturing Practice (GMP) standard with its advanced systems and facilities. The company currently procures the blood plasma it needs from seven depositories in total, including six in Anhui and one in Hunan.

A subsidiary of GC China, GC Chinapharm is a pharmaceutical wholesaler established by GC Pharmaj for the distribution of pharmaceutical products in China. The company is expected to buttress GC China’s continued growth through effective marketing and distribution of GC China products to local clients. Gelinker currently operates six distributorships across the nation, including the main one at Shanghai.

The holding company of GCBT, GCNA provides efficient financing for GCBT.

Established in Montreal as a forward base for launching into the plasma-derived product market in North America, GCBT is currently building its plant. The products it will produce will mainly target the advanced North American markets in the United States and Canada after the authorities’ approval.

• GC America was established to ensure a stable supply of materials for Green Cross plasma-derived products as well as to ensure the company’s presence and effective operation in the U.S. market.

• Mogam Institute for Biomedical Research was founded in 1984 by GC Pharma using the proceeds from the hepatitis-B vaccine that it developed.
• The founding mission of the Mogam Institute is to contribute to society by developing advanced biotechnology and reinvesting proceeds into ongoing research and development. The Mogam Institute was the first-ever nonprofit research foundation set up by a private-sector entity in Korea after gaining approval from the Ministry of Science & Technology (now the Ministry of Science, ICT & Future Planning).

• GC Labs, founded as an agency for clinical trials and research in 1982, has been pioneering medical research and clinical trials in Korea and abroad. The organization today has partnerships with prestigious clinical testing organizations worldwide, cutting-edge equipment and facilities, and a talented and dedicated research staff, all of which make it possible for the organization to develop specialized and innovative diagnostic procedures.
• GC Labs performs all tests and trials in a state-of-the-art facility boasting a total floor area of well over 12,000 square meters. In addition to operating such a facility, the first in Korea to be designed and built exclusively for clinical trial and research purposes, GC Labs has also become the first research agency in Korea to be awarded the ISO 9001 Quality Management Certificate and the ISO 14001 Environmental Management System Certificate together in 2008.
• Cutting-edge, all-automated systems allow GC Labs to handle over 4,000 tests a year. With its testing facilities open and running 24/7/365, GC Labs performs the greatest number of special tests in Korea today.

• GC i-Med is a center for functional medicine and diagnostics that was established in 1982 with the founding mission of rejalizing a healthy society for all. Equipped with the latest IT systems and diagnostic and care programs, the organization provides customized medical examination services for clients of all ages.
• GC i-Med, with its 64-channel MDCT, 1.5T MRI, and other cutting-edge medical devices and systems, as well as its talented and experienced medical staff, offers a wide range of medical services. It is a pioneering figure in the world of healthcare and medical examinations in Korea, providing a diagnostic program through partnerships with other leading medical institutions.

• As the only bio-engineering and construction company in Korea, GCEM has broken its annual revenue records every year since its establishment in 2001. The company today leads in construction of cutting-edge biotechnology facilities that satisfy some of the world’s most rigorous standards for quality and safety, such as Good Manufacturing Practice (GMP) and Biosafety Level (BSL).
• The accomplishments of this construction company, which is increasingly playing a pivotal role in the Korean biotechnology industry, includes the GMP-certified Ochang plant and the Hwasun plant, both operated by GC Pharma, with the latter being the only facility in Korea that produces flu vaccines. In 2013, the company also built a BSL 4 research facility for the Korea Centers for Disease Control and Prevention (KCDC).

Boasting quarantine and containment systems of the highest quality, Invacfarm produces and supplies fertile eggs from its state-of-the-art poultry farm and hatcheries, which meet the standard for vaccine production. Invacfarm provides a steady supply of quality eggs to GC Pharma, performing an indispensable role in the company’s development and production of flu vaccines.